Avilar Therapeutics develops ASGPR Targeting Chimeras (ATACs) to degrade extracellular and membrane-bound proteins, addressing the challenge of targeting nearly 40% of human proteins implicated in various diseases. Their proprietary drug discovery platform enables the design of novel degraders aimed at establishing new treatment standards for serious medical conditions.
Funding
$75.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many human proteins implicated in diseases are located outside cells, but traditional protein degradation methods primarily target intracellular proteins. This leaves a significant portion of the proteome inaccessible to targeted degradation therapies.
Solution
Avilar Therapeutics is developing ASGPR Targeting Chimeras (ATACs), a novel class of protein degraders designed to target extracellular and membrane-bound proteins. ATACs harness the natural degradation machinery of the endolysosome to remove disease-causing proteins located outside of the cell. The company's proprietary drug discovery platform enables the rational design and assembly of ATACs against a wide array of extracellular targets, expanding the scope of protein degradation as a therapeutic modality. This approach aims to establish new treatment standards for serious medical conditions by addressing previously undruggable extracellular proteins.
Target Audience
The primary target audience includes patients suffering from serious diseases caused by extracellular or membrane-bound proteins, as well as pharmaceutical companies seeking novel therapeutic modalities.
Features
- ATACs (ASGPR Targeting Chimeras): A novel class of degrader molecules.
- Targets extracellular and membrane-bound proteins.
- Leverages the endolysosome pathway for protein degradation.
- Modular drug discovery platform for rapid ATAC design and assembly.